Polarean Imaging Share Discussion Threads

[hedgehog 100] 17/9/2019 14:01

Some relevant news from GE Healthcare, which is using AI to improve CT imaging of lungs. -

"GE Healthcare Receives FDA Clearance of First Artificial Intelligence Algorithms Embedded On-Device to Prioritize Critical Chest X-ray Review
Sep 12, 2019
• Helps radiologists prioritize critical cases with a suspected pneumothorax – a type of collapsed lung – by immediately flagging critical cases to radiologists for triage, which could drastically cut the average review time from up to eight hours[1]
• Offers first-of-its-kind automated AI quality check features that detect acquisition errors, flagging images for technologist review and allowing them to make corrections before they go to radiologists for review
WAUKESHA, Wis., September 12, 2019 – GE Healthcare today announced the Food and Drug Administration’s 510(k) clearance of Critical Care Suite, an industry-first collection of artificial intelligence (AI) algorithms embedded on a mobile X-ray device. Built in collaboration with UC San Francisco (UCSF), using GE Healthcare’s Edison platform, the AI algorithms help to reduce the turn-around time it can take for radiologists to review a suspected pneumothorax, a type of collapsed lung. ..."


GE Healthcare unveiled its Critical Care Suite on 26th. November last year, and its 510(k) application was shown as pending with the FDA at that time. -



POLX has of course developed an MRI scanning technology for lungs, which it is promoting as being superior to "Standard CT". -


It would be interesting to know how POLX's technology compares to AI-enhanced CT scanning for lungs.

[slicethepie] 11/9/2019 10:42

At least the share price weakness associated with amp drip feeding their stake is giving pi a chance to buy as suspect if the whole of Amp stake were placed we would not get the opportunity.

[mcfly79] 11/9/2019 10:32

Let's hope they have the choice.

We should get told about 100% enrolment soon but I think result will be 4-6 weeks after that.

[richardjohn10] 11/9/2019 10:21

They'll sell into results news

[mcfly79] 11/9/2019 09:54

Amphion have sold another 1.15m shares and now hold 17,122,523 shares.

The RNS from Amphion contains a few more details:



Amphion's loan is due at the end of September and is secured by the pledge of the remaining 17,122,523 shares.

[aimsurfer] 30/8/2019 08:59

I think rumours based on last RNS. If they do need to sell down more than they want I'm sure they or the BOD will be able to find buyers. Especially at these levels. I've started to scale in past few days.

[si c] 30/8/2019 08:32

Is AMP selling confirmed? ....or a guess?

[richardjohn10] 28/8/2019 11:07

Polx shares for the mid to long term holder is a no brainer

[kj kelley] 28/8/2019 10:32

Amphion's may not have the luxury of selling into the news.

Loan favility is due to be repaid on 30th September 2019. It has pledged it's Polarean shareholding against this debt. It is trying to refinance or extend this debt. As the debt is effectively to allow Amphion to speculate on the price of POLX shares, I would be surprised if lenders would provide more funds to Amphion, especially in the current financial climate.

The debt outstanding is $2.8m against which POLX shares are pledged. The value of the POLX shares was $5.3m on 9th August and is now worth $4.8m. Of this $4.8m the lenders are entitled to 15% of the aprreciation above 18p share price of POLX, whcih is around $0.2m currently.

So we might see the lender acquiring POLX shares in repayment of the debt and these shares being sold.

Amphion has a market cap of £0.3m and the company's total debt is $30.3m. It's accounts have not been published as the auditors are continuing work in relation to the going concern status of the company.

It seems that Amphion is very close to being declared bust. If so this will create a substantial overhang in Polarean's shares. This years placing at 18p showed that there was demand for the shares at that price. Althought market conditions have chnaged since then.

[hulk2004] 16/8/2019 09:54

That will be shifted easily over next 6-8weeks with news coming up, think they have sold a couple of 100k since then, director just bought £80,000 in last placing, he must be very confident, also only 125 million shares in issue I think.

[richardjohn10] 16/8/2019 09:35

They will sell into the news

[hamidahamida] 16/8/2019 07:55

Massive overhang share price KillerAmphion now holds 18,272,523 ordinary shares in Polarean representing 15.97% of the issued share capital with voting rights. The full TR-1 disclosure is set out below.

[richardjohn10] 14/8/2019 12:41

They don't want to sell because they know what's on the way!No brainer this stock.CEO buying shed load gives me plenty confidence.

[sja123] 12/8/2019 14:07

Covered on V O X again today by an analyst from share price Angel



He believes they are undervalued quite some way taking into account their Phase III stage....most drug companies at this stage of development have a much higher valuation....and a much higher chance of failure compared with Polarean...which is pitching a new drug/device tech against a much older and inferior test....

He explains quite well that the Polarean system is unique in that it will be the first time pulmonary consultants will have a clinical test available that actually shows gas exchange between lungs and blood....the present scintigraphy system they are testing against is a snapshot....a picture in time....whereas Polarean tech is, for want of a better comparison, a video....where the whole pulmonary system can be investigated.....and show gas exchange straight into the blood....

Because they can "light up" the polarized xenon....they are also investigating the possibility of this type of test being developed for use in cardiac diagnosis as well....

Worth a listen if you're researching this company....

[global nomad] 09/8/2019 17:19

little surprise at the end there...

[mcfly79] 07/8/2019 08:00

Hi all,

I'm researching the company.

In the investor symposium Q&A it was stated that under Hatch-Waxman the company should get 5 years of market exclusivity for their Xe129 consumables.

Does anyone know what happens after 5 years? Can other people start selling their own Xe129 to be used with the machines?

Thanks

[robertjbeck] 02/8/2019 15:21

https://hbr.org/2019/08/4-ways-to-make-evidence-based-practice-the-norm-in-health-care?utm_campaign=hbr&utm_source=twitter&utm_medium=socialAccording to this research in Harvard Business Review it takes on average 17 years to adopt new clinical practices

[someuwin] 01/8/2019 11:18

Razor-razorblade model: Unit sale and recurring drug revenue

Polarean is seeking FDA approval as a drug-device combination. If approved, customers using Polarean’s system (‘device’;) will have to use the Company’s 129Xe gas (‘drug’), also exclusively sourced through Polarean. This razor-razorblade model provides the Company with a recurring drug revenue for each patient scanned using the system.

[someuwin] 01/8/2019 10:09

• Completion of 80-patient Phase 3 trial (data expected in Q4 2019) to drive clinical unit sales
• First clinical unit sales expected in H2 2020
• Currently selling units to research institutions
• Scope for potential partnerships with big pharma in the near-term

Polarean Imaging plc (Polarean) is a revenue-generating company developing a drug-device combination for the magnetic resonance imaging (MRI) market. The Company’s gas polarisation platform provides a non-invasive, radiation-free method to visualise lung structure and function using MRI.

The annual burden of pulmonary disease in the US is estimated to be over US$150b. The addition of Polarean’s technology is expected to increase the asset utilisation and profitability of a customer’s MRI system, whilst enabling earlier diagnosis.

The Group is currently running two Phase 3 trials for its drug-device platform. The trials are expected to complete enrollment in Q3 2019 and, if successful and approved by the US Food and Drug Administration (FDA), we expect will enable clinical sales of its system, starting by H2 2020.

Although yet to receive clinical-approval, Polarean has already sold several polarisers to medical research institutes and remains focused on expanding the installed base of systems through additional sales of research units. Not only is this a source of revenue but it also underlines the academic acceptance of the Group’s technology.

We initiate coverage with a BUY rating and a 53p price target.

[someuwin] 01/8/2019 09:36

Just been reading the recent share price Angel broker note. Have to say this stock looks fantastic.

[sja123] 01/8/2019 08:30

You're most welcome GN....nice to see you here....

[global nomad] 01/8/2019 08:29

thanks for the good posts sja, bought in a couple of weeks ago and have added this morning.

[richardjohn10] 31/7/2019 13:04

I've taken the plunge! Looking forward to the results!